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Faranak Sharifi1, Nima Hojeghani2, Saeideh Mazloomzadeh1 and Zahra Shajari1,3*Abstract
Background: Postprandial hypertriglyceridemia in diabetes mellitus can be followed by endothelial dysfunction,
impaired vascular compliance and increased cardiovascular complications. So focus on better control of
postprandial hypertriglyceridemia is as important as controlling fasting triglyceride level in type 2 DM.
Objective: We evaluated the effect of ezetimibe adding to fibrate or statin on postprandial hypertriglyceridemia.
Methods: In a randomized controlled clinical trial, 47 subjects with type 2 diabetes and hypertiglyceridemia were
enrolled and divided in three treatment groups including Gemfibrozil 1200mg/d + placebo(group A), Ezetimibe10mg/d +
Gemfibrozile 1200mg/d(group B) or Ezetimibe10mg/d + Atorvastatin10mg/d (group C) for a 6- week period. Oral fat
loading test were performed in the initiation and also at the end of the study and lipid profile and APOB were
measured.
Results: Fasting and postprandial serum triglyceride (TG) decreased significantly with all the three treatment groups
with no difference between them in the percent of TG reduction. Although serum total cholesterol decreased
significantly in all the three groups of treatment its reduction was more prominent in group C(−38.1% ± 11.2%in group
C vs. -16.5% ± 19.6% and −7.2% ± 10.7% in groups B & A respectively, p < 0.0001 ). Fasting serum HDL increased
significantly only by Gemfibrozil (23.4% ± 28.4% vs. 6.4% ± 18.9% and 1.8% ± 17.7%, p < 0.05 ). Fasting serum APOB was
reduced only in ezetimibe containing groups (B &C).
Conclusion: Adding ezetimibe to gemfibrozil has no additional effect on reducing postprandial TG but ezetimibe can
potentiate the effect of low-dose atorvastatin on lowering TG and LDL-c.
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Type 2 diabetes is associated with abnormalities in post-
prandial triglyceride concentrations that are considered
as independent cardiovascular risk factors. Based on
some studies on humans, both increased secretion and
reduced catabolism of apoB containing lipoproteins are
responsible for over-accumulation of them in patients
with type 2 diabetes and then hypertriglyceridemia [1].
Although fibrates and statins improve many aspects of
dyslipidemia in diabetes mellitus, many patients do not* Correspondence: adz.shajari@gmail.com
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reproduction in any medium, provided the ortouch the goals [2]. So combination therapies with
existing lipid-lowering agents are attractive options to
control dyslipidemia. Addition of a fibrate to statin ther-
apy can further increase HDL-C and lower TG levels.
Between the fibrates, gemfibrozil has the greatest poten-
tial to interact with statins. However, this combination is
associated with an increased risk of side effects, particu-
larly myopathy and abnormal liver function tests [3,4].
A new therapy for dyslipidemia treatment is a selective
intestinal cholesterol absorption inhibitor, ezetimibe.
Ezetimibe inhibits the intestinal absorption of dietary
and biliary cholesterol without interfering with the ab-
sorption of fat-soluble vitamins. Ezetimibe is a safe and
well-tolerated treatment without clinically important
drug interactions. Ezetimibe is assumed to producestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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when uses in combination with other lipid-lowering
agents [5]. It was shown that the co-administration of
ezetimibe with other lipid lowering agents can be
generally well tolerated. For example, co-administering
ezetimibe with on-going simvastatin 10 or 20 mg treat-
ment allowed more hypercholesterolemic patients with
chronic heart disease to reach the LDL-C treatment target
[6] or a 6-week ezetimibe and simvastatin therapy, com-
pared to simvastatin alone, was presented to have a posi-
tive influence on both fasting and postprandial lipoprotein
profile in type 2 diabetic patients by favoring the produc-
tion of cholesterol-poor chylomicrons and VLDL particles
that have less atherogenic potential [7].
The potential effects of ezetimibe have been scarcely
evaluated and few data are available in type 2 diabetes
patients with hypertriglyceridemia. To determine the ef-
fect of co-administering ezetimibe with statin or fibrate
on fasting and postprandial lipid profile especially post-
prandial TG concentrations of patients with DM, a
double clinical trial has been designed.
Materials and methods
This study is a randomized; double-blind clinical trial
approved by the Ethics Committee of Zanajn Univer-
sity of Medical Sciences, and registered in Iranian
registry of clinical trials (www.irct.ir) with this code:
IRCT201105311179N5.
Subjects
Seventy-five patients with type 2 DM were selected ran-
domly from the patients who referred to diabetes clinic
of vali-e-asr hospital, a referral academic hospital, in
Zanjan. All the subjects were less than 60 years old, with
acceptable control of DM(HbA1c < 8%) in the last 6
months and fasting TG levels more than 250 mg/dl,
LDL-C less than 190 mg/dl and had no medication
which affects serum lipid concentrations. Those people
with renal dysfunction (GFR < 60 ml/min) or other co-
morbidities such as acute or chronic liver disease,
thyroid dysfunction, cushing syndrome, acromegaly and
malignancy were excluded. After an initial two weeks to
test eligibility of the patients 59 subjects approved to
enter in the study. Written informed consent was
obtained from all the subjects before the study.
An information form including demographic and med-
ical data of the subjects was completed for all of the par-
ticipants. To analyze the dietary content for the subjects,
three samples of 24 –hour food recall forms were used
at the beginning and also after the intervention. Calorie
intake and macronutrient content of the participants'
diet were analyzed by nutritionist IV version 3.5.2 soft-
ware. Physical activity score of the subjects was deter-
mined by a standard short form of previous 7 –dayphysical activity questionnaire [8] before and after re-
ceiving the treatments.
Measurements
Height, weight and waist circumference of the patients
were measured by standard methods and body mass
index (BMI) was calculated for all the participants. Blood
pressure was measured two times with a 15- minute
interval in sitting position and the mean of them was
recorded for each of the patients. All the measurements
repeated after the end of the study.
Blood samples were collected at baseline to measure
serum lipid profile (TG, total cholesterol, LDL-C, HDL-C),
fasting plasma glucose (FPG),thyroid stimulating hormone
(TSH), liver function tests (AST, ALT, Alkaline phosphat-
ase), serum creatinine concentration(Cr), APO B and
HbA1c. All blood samples for the assessment of lipid pro-
file were obtained after 14 hours of fast. All the laboratory
measurements were conducted at the central laboratory of
Vali-e-asr Hospital.
Serum total cholesterol, TG,LDL-C, Cr, AST, ALT, Alp
and FPG were measured enzymatically using photomet-
ric method by autoanalyser [Minbray (BS-120)] and Pars
Azmun kits. HDL-C was measured after precipitation of
the apolipoprotein B-containing lipoproteins (LDL-C and
very low density lipoprotein [VLDL]) in whole plasma by
heparin-manganese chloride. LDL-C was calculated by the
method of the Friedewald equation in cases with TG
concentrations less than 400 mg/dl. Apolipoprotein
(apo) B were determined by Immuno Turbidimetry
using ROCH kit and COBAS Integra device. HbA1c was
measured in whole blood by borolated affinity method
and nyco card kits.
Oral fat load (cookie test)
For fat loading, a cookie test was performed after over-
night fasting for at least 14 h. The cookie consisted of
66 g carbohydrate (60 g wheat and corn contained
bread), 41 g fat with 25 g saturated fat and 6.5 g protein
(50 g butter + 45 g date palm) for a total of 650 kcal [9].
The participants were instructed to ingest the cookie
within 15–20 min. Time measurement was started when
half of the cookie had been ingested. Participants
remained supine during the test and were only allowed
to drink water. Venous blood samples were drawn 4 h
after the fat load for serum TG, total cholesterol, LDL,
and HDL. Samples were immediately put on ice. Plasma
was isolated and stored at -70C for further analyses.
Study protocol
At the initiation of the study, qualifying patients were
randomly assigned to one of three treatment groups:
gemfibrozil + placebo, gemfibrozil + ezetimibe and ator-
vastatin + ezetimibe. Each of the patients received a
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how to use the medications for 6 weeks. The investigator
was blind of the content of the packages. Package a
contained gemfibrozil capsules [(300 mg) Abidi Labora-
tory Company] plus placebo tablets apparent like
ezetimibe. Atorvastatin tablets [(10 mg) Sobhan Daru
Company] plus ezetimibe tablets [(10 mg) Alborz Daru
Company] were packed in Package B and package C in-
cluded gemfibrozil capsules plus ezetimibe tablets.
Group A received gemfibrozil 1200 mg/d plus one
tablet of placebo, group B treated with gemfibrozil 1200
mg/d plus one tablet of ezetimibe (10 mg/d) and group
C received atorvastatin tablets (10 mg/dl) plus ezetimibe
tablets (10 mg/dl) [10]. All the subjects treated for 6
weeks. Because of existence of powerful evidences for the
more effectiveness of combination therapy with ezetimibe
and statin compared to monotherapy with these medica-
tions on lowering LDL-c and TG with lower side effects,
we omitted the group taking atorvastatin alone or
ezetimibe alone in our study.
Safety was evaluated through patient reports for ad-
verse events, investigator observations, laboratory tests,
physical examinations, and vital signs. Investigators were
not blinded to safety laboratory results. Possibility of
direct contact with the physician was established to an-
swer patients' questions. We considered hepatic side ef-
fects for the medications when rises in AST or ALT
were more than three times of the upper limit of normal
range and reconfirmed by a second evaluation. All the
subjects with significant side effects advised to discon-
tinue the medications and the data were recorded.
After 6 weeks of the treatment, patients were recalled
again for reevaluation of the variables have been measured
before the intervention including anthropometric and
clinical measures, oral fat load test and all the laboratory
tests except TSH and Cr. complement of 24–hour food
recall form and previous seven –day physical activity
questionnaire were done again for all the participants.
Statistical analysis
A sample size of 25 in each group was calculated based
on 0.25 differences of TG means and assuming a stand-
ard deviation of 0.3, a power of 80%, and a significance
level of 5%. The power for 16 patients in each group,
using the above information, was 65%.
Data are expressed as mean ± SD. We analyzed mean
percentage changes from baseline in fasting and postpran-
dial TG, total cholesterol, LDL-C, HDL-C and Apo B after
6 weeks of treatment between the three groups, using an
analysis of variance (ANOVA). Differences between the
two groups were evaluated by t-tests. Paired t-test was
used to evaluate the changes in one group before and after
the intervention. Non-parametric tests were used to
analyze the data of variables without normal distribution.Simple and multivariate regression analysis was used
to determine the correlations between the variables. P
values less than 0.05 were considered statistically signifi-
cant. The statistical analysis was performed according to
standard methods using the Statistical Package for Social
Sciences software 16.
Results
Patient accounting and characteristics at baseline
A total of 75 patients were screened at baseline for this
study. Of these, 59 patients were eligible and enrolled.
Totally twelve patients excluded and did not complete
the study including: two with side effects that both of
them were gastrointestinal complications and were in
group A (gemfibrozil alone), and ten who didn't want to
do oral fat load test for final evaluation. The remaining
47 eligible patients were assigned in 3 groups as follows:
14 subjects in group A treated with gemfibrozil + pla-
cebo, 16 patients in group B who received ezetimibe +
gemfibrozil, and 17 participants in group C with receiv-
ing ezetimibe + atovastatin. With this number of partici-
pants the power of the trial estimated to be 80%. Patient
characteristics at baseline are shown in Table 1.
Mean age of all subjects was 51.8 ± 10.1 years old with
mean duration of DM 6.4 ± 5 years. Thirty two of the
participants were taking oral hypoglycemic agents for
their diabetes control, one subject was controlled with
insulin and twelve were receiving combination therapy
with insulin and oral hypoglycemic agents. Two of the
patients were controlled with diet alone. There was no
considerable difference between the three groups regard-
ing the mode of treatment to control hyperglycemia.
No significant differences were found between the
three intervention groups for basal serum levels of
fasting and postprandial (after fat load test) lipid profile,
HbA1c, TSH, Cr and apoB. Data about the diet content
and physical activity score of the participants is shown
in Table 2. There were no significant changes in calorie
intake and physical activity of the subjects within and
between the groups before and after the intervention ex-
cept for group c that had higher calorie intake from fat
after the intervention.
Administration of ezetimibe, atorvastatin and gemfi-
brozil was well tolerated.
In general, the types of adverse events resulting in treat-
ment discontinuation or interruption were no more com-
mon or severe in any treatment group. No patient died
during the study. No significant elevations in hepatic en-
zymes were seen, and no cases of hepatitis, jaundice, or
other clinical signs of liver dysfunction were reported.
Fasting lipid profile after treatment
Six weeks treatment of hyperlipidemia in 47 DM pa-
tients resulted in a significant decrease in serum fasting
Table 1 Baseline clinical and laboratory characteristic of participants in the three treatment groups
Variables Group A Group B Group C Total P value
(Gemfibrozil) (Ezetimibe + Gemfibrozil) (Ezetimibe + Atorvastatin)
(N = 14) (N = 16) (N = 17) (N = 47)
Clinical characteristics
Sex
Male/Female 5/9 5/11 5/12 15/32 0.93
Age (y) 54.2 ± 8.2 51.3 ± 10.5 50.2 ± 11.3 51.8 ± 10 0.54
DM duration (y) 8.1 ± 5.7 5.2 ± 3.3 6.1 ± 5.6 6.4 ± 5 0.28
Hypertension (%) 10 (71.4) 8 (50) 8 (47.1) 26 (55.3) 0.34
BMI (kg/m2) 30 ± 3.8 31.3 ± 4.2 29.8 ± 4.5 30.4 ± 4.1 0.54
Cigarette smoking (%) 1 (7.1) 1 (6.2) 3 (17.6) 5 (10.6) 0.5
Retinopathy (%) 4 (6.28) 2 (5.12) 1 (9.5) 7 (9.14) 0.19
Neuropathy (%) 4 (6.28) 5 (2.31) 7 (2.41) 16 (34) 0.73
Cardiovascular disease (%) 1 (6.2) 1 (6.2) 0 2 (4.3) 0.54
Laboratory test
FPG (mg/dl) 110 ± 25 130 ± 37 145 ± 36 .0191
FTG 343 ± 128 351 ± 121 307 ± 117 0.56
F Chol 231 ± 47 207 ± 36 220 ± 36 0.3
F HDL-c 40 ± 8 35 ± 8 45 ± 13 0.0481
HbA1c 7.7 ± 1.9 7.8 ± 1.2 7.9 ± 0.9 0.88
Apo A 147 ± 19 144 ± 20 156 ± 26 0.33
Apo B 100 ± 19 93 ± 19 92 ± 16 0.36
PL TG 451 ± 155 462 ± 138 429 ± 141 0.81
PL Chol 228 ± 44 209 ± 36 222 ± 36 0.44
PL HDL-c 36 ± 8 33 ± 7 42v15 0.85
Abbreviations: DM Diabetes Mellitus, BMI Body mass Index, FPG Fasting Plasma Glucose, FTG Fasting Triglyceride, F Chol Fa Post Fat Load sting Cholesterol, F HDL-
c Fasting High Density Lipoprotein, PL TG Post Fat Load Triglyceride, PL Chol Post Fat Load Cholesterol, PL HDL-c Post Fat Load High Density Lipoprotein.
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pare to group C the reduction rate for fasting TG was
more prominent in groups A and B which containing
gemfibrozil. Moreover no additional effect was seen in





Before After P-value Before
Total calorie intake (kcal) 1330 ± 607 1333 ± 527 0.968 1390 ± 435
Percent of calorie intake
from fatty acid (%)
21.4 ± 7.5 17.5 ± 6.6 0.13 14.7 ± 6.6
Fat intake(g) 31.6 ± 16.4 26.7 ± 13.7 0.32 23.8 ± 13.5
Carbohydrate intake (g) 202.9 ± 95 234.6 ± 91 0.12 232.7 ± 74
Protein intake (g) 59.7 ± 31.3 52 ± 30.2 0.31 63.5 ± 36.8
Physical activity score −2.6 ± 13.6 0.9 ± 17.9 0.62 −2 ± 10.5
1-P value <0.05 is considered significant.A regarding to reducing fasting serum TG(−175 ± 153
mg/dl reduction in serum fasting TG by ezetimibe plus
gemfibrozil, and −176 ± 80 mg/dl by gemfibrozil alone).
Total serum cholesterol also decreased in all of the
groups (P < 0.05), but was more remarkable in thoseithin and between the groups before and after the
Group B Group C P value
(between
groups)
ibe + Gemfibrozil) (Ezetimibe + Atorvastatin)
(N = 16) (N = 17)
After P- value Before After P- value
1435 ± 539 0.69 1281 ± 454 1369 ± 448 0.394 0.82
17.7 ± 8.2 0.15 15.7 ± 5.4 20.5 ± 9.6 0.05 0.0181
29.9 ± 19 0.2 23.6 ± 15.2 30.1 ± 15.8 0.1 0.26
243.1 ± 93 0.65 221.4 ± 74 213.3 ± 89 0.14 0.63
52.4 ± 19.8 0.15 49.5 ± 19.4 62.4 ± 32.4 0.14 0.38
−4.1 ± 8 0.48 7.5 ± 18.2 5.1 ± 18.5 0.64
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C) (38 ± 11% reduction in group C versus 7% reduction
in group A and 16% reduction in group B, P:0.0001).
LDL-c decreased significantly in group B and C who
were treated with ezetimibe plus gemfibrozil or atorva-
statin (p < 0.0001), but a non significant increment in
LDL-c was seen with gemfibrozil alone (group A). Apo
B reduction was seen in groups B and C which
containing ezetimibe (p: 0.04) and was more prominent
in group C (Table 3). HDL-c increased significantly only
in group A who were under treatment with gemfibrozil
alone (p: 0.014).
Postprandial lipid profile after treatment
Post fat load test TG level reduced significantly in all the
three intervention groups (Table 3). There was no differ-
ence between the groups for the reduction rate of post-
prandial TG level (52 ± 17% reduction in group A versus
46 ± 24% in group B and 35 ± 24% in group C,P:0.1).
Post fat load test total cholesterol and LDL-c levels
showed significant reduction in all the three groups of
intervention, but was more greater by ezetimibe plus
atorvastatin (38 ± 11% reduction in postprandial total
cholesterol in group C versus 15 ± 17% reduction in group
B and only 9 ± 11% in group A, p: 0.0001) (Table 3). Al-







Before After P value Before
TG (mg.dl) 351 ± 121 175 ± 85 <0.00011 343 ± 128
T-Chol (mg.dl) 207 ± 36 191 ± 31 0.0341 231 ± 47
HDL (mg.dl) 35 ± 8 42 ± 5 0.0141 40 ± 8
LDL (mg.dl) 101 ± 48 113 ± 35 0.15 125 ± 41
FBS (mg.dl) 130 ± 32 131 ± 35 0.86 110 ± 1.9
HbA1C (%) 7.8 ± 1.2 7.9 ± 1.4 0.65 7.7 ± 1.9
APOA1 (mg.dl) 144 ± 20 138 ± 22 0.23 147 ± 19
APOB (mg.dl) 93 ± 19 94v20 0.6 100 ± 19
AST (IU.L) 26 ± 9 30 ± 8 0.076 29 ± 11
ALT (IU.L) 25 ± 12 25 ± 13 0.9 26 ± 12
Alk.p (IU.L) 274 ± 135 234 ± 105 0.041 207 ± 63
(post fat load)
TG (mg.dl) 436 ± 138 221 ± 109 <0.00011 451 ± 155
Choesterol (mg.dl) 209 ± 36 188 ± 33 <0.00011 228 ± 44
LDL-c (mg.dl) 101 ± 39 106 ± 33 0.59 109 ± 38
HDL-c (mg.dl) 33 ± 7 40 ± 5 0.0091 36 ± 8
1-P value <0.05 is considered significant.
2-TG triglyceride, T_Chol total cholesterol, HDL High Density lipoprotein, LDL Low D
Thyroid Stimulating Hormone, APOA1 Apoprotein A1, APOB1 Apoprotein B1.groups specially in group A the difference between the
groups was not statistically significant (Table 3).
Finally, Multivariate regression analysis demonstrated
that the reduction rate of fasting and postprandial TG
level was inversely correlated with baseline serum fasting
and postprandial TG concentration (p: 0.008). Other
confounding factors like age, sex, duration of diabetes,
BMI, baseline calorie intake and percent of calorie intake
from fat had no significant effect on the changes of
serum TG with the treatments (Table 4).
Discussion
A gap between lipid goals and what we reach in clinical
practice leads us to investigate and find the best combin-
ation protocol for diabetic patients with hyperlipidemia. In
this trial, fasting and postprandial serum triglyceride (TG)
and cholesterol decreased significantly with all of the three
modes of treatment. Adding ezetimibe to gemfibrozil not
only had no further effect on lowering fasting TG but also
might attenuate the beneficial effect of gemfibrozil on
postprandial TG and HDL-C. However co-administering
gemfirozil and ezetimibe improved the effect of gemfibrozil
on total cholesterol, LDL-c and Apo-B concentrations. The
best effect on serum fasting and postprandial total choles-
terol and also LDL-c was seen with combination of
ezetimibe and atorvastatin (38% reduction rate).ariables before and after treatment in each of the three
Group B Group C
timibe + Gemfibrozil) (Ezetimibe + Atorvastatin)
(N = 16) (N = 17)
After P value Before After P value
168 ± 53 <0.00011 307 ± 117 202 ± 85 0.0021
188 ± 41 0.0071 220 ± 36 136 ± 32 <0.00011
42 ± 7 0.35 45 ± 13 45 ± 13 0.98
112 ± 39 0.38 116 ± 29 50 ± 17 <0.00011
118 ± 0.8 0.32 145 ± 36 138 ± 48 0.58
7.5 ± 0.8 0.63 7.1 ± 0.9 7.9 ± 1.6 0.81
136 ± 35 0.0191 156 ± 26 151 ± 27 0.01
91 ± 22 0.04 92 ± 16 55 ± 13 <0.00011
29 ± 13 098 22 ± 8 23 ± 5 0.56
24 ± 13 0.73 21 ± 10 23 ± 15 0.68
183 ± 63 0.1 204 ± 66 204 ± 50 0.97
216 ± 66 <0.00011 429 ± 141 267 ± 104 <0.00011
190 ± 40 <0.00011 222 ± 36 137 ± 33 <0.00011
106 ± 37 0.79 106 ± 32 47 ± 18 <0.00011
40 ± 8 0.0331 42 ± 15 43 ± 13 0.776
ensity lipoprotein, FPG Fasting Plasma Glucose, HbA1C Hemoglubin A1C, TSH
Table 4 Result of multivariate regression analysis for
percent of reduction in fasting and post fat load










Baseline BMI 0.247 0.067










Baseline BMI 0.26 0.07




Baseline fasting TG −0.314 0.0351
1-P value <0.05 is considered significant.
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tics of a second drug to complement either statins or
fibrates as the first-line treatment options for dyslipidemia
in diabetic patients [7,11].
Ezetimibe is a hypocholesterolemic drug that select-
ively inhibits intestinal cholesterol absorption. Beside the
effect on LDL-c levels, an additional property related to
reducing metabolism of long-chain fatty acids and
blocking apo-B48 formation might be the mechanism of
chylomicron lowering effect of ezetimibe [12]. Further-
more, ezetimibe might reduce cholesterol availability for
VLDL endogenous synthesis in the liver and affect
hypertriglyceridemia [13]. Also, new animal based re-
searches revealed that treatment with ezetimibe not only
inhibits cholesterol uptake, but may also modulates
intestinal function and improves dietary lipids handling
and reduces chylomicron production. These, in turn,
promote decreases in fasting and postprandial lipid
levels and improvements in glucose homeostasis [14].
Studies on ezetimibe monotherapy in randomized pro-
spective trials have been shown that ezetimibe decreases
fasting and postprandial TG and apoB levels after the fat
loading test [15,16].
Statins are considered to play a main role in lowering
LDL-C. High dose of statins are associated with more
side effects like myopathy and rising liver enzymes. Fur-
thermore, most of diabetic patients suffer from com-
bined hyperlipidemia. Therefore combination therapy
with lipid-lowering drugs is mandatory in many of dia-
betic patients. Although no differences were found in
fasting lipid profiles between low-dose simvastatin withezetimibe and monotherapy with high-dose of simva-
statin in one study [17] when co-administered with
atorvastatin, ezetimibe resulted significant incremental
reductions in LDL-C and triglycerides and increased in
HDL-C and was well tolerated, with a safety profile simi-
lar to atorvastatin alone or to placebo [18,19].
In many other studies with different designs and popu-
lations of patients, ezetimibe co-administered with all
doses of current statins caused significant incremental
reductions in LDL-C and allowed more patients to reach
LDL-C goal compared to the respective dose of statin
monotherapy. For example in Japanese patients with type
2 diabetes or impaired glucose tolerance and coronary ar-
tery disease, adding ezetimibe (10 mg/day) to atorvastatin
(10 mg/day) significantly improved the lipid profile
compared with atorvastatin monotherapy at 20 mg/day
[20,21]. We also found a significant reduction in the con-
tent of total cholesterol, LDL and TG after combination
therapy with atorvastatin and ezetimibe both at fasting
and postprandial phase, although the percent of calorie in-
take from fat was higher after the intervention in the par-
ticipants.This significant reduction of TG and LDL in the
presence of higher fat intake in group C shows a potent
lipid- lowering effect of combination of ezetimibe and
statin. One of the limitations of the present study was ab-
sence of a group with statin mono therapy. Because of ex-
istence of powerful evidences for the more effectiveness of
combination therapy with ezetimibe compared to statin
monotherapy on lowering LDL-c and TG with lower side
effects, we omitted the group taking atorvastatin alone in
our study.
Consistent with previous findings [16,17,22,23], our in-
teresting finding showed statistically significant post-
prandial TG reduction response rather than fasting TG
reduction in all types of the interventions. Routinely, we
measured triglyceride levels in fasting blood specimens;
but evidence shows that postprandial triglycerides further
increase oxidative stress and is considered as a contribut-
ing factor to endothelial dysfunction, atherosclerosis, and
cardiovascular disease.
The mechanisms of fasting and postprandial increases
of TG and intestine-derived lipoproteins in diabetes are
supposed to be slower clearance of these particles and/
or a reduced activity of lipoprotein lipase (LPL) specific-
ally related to type 2 diabetes [24,25].
When triglycerides are high, the first approach can be
intensified using an LDL lowering and reaching the low-
density lipoprotein cholesterol (LDL–C) goal of <130
mg/dl. The second approach used with caution is the
addition of nicotinic acid or a fibrate drug [26].
Fibrate is a PPAR-α agonist and used to treat hypertri-
glyceridemia and mixed dyslipidemia. It is approved for
the treatment of dyslipidemia commonly in patients at
high risk of cardiovascular disease, including Type 2
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triglycerides, raises HDL-cholesterol and decreases con-
centrations of small LDL-cholesterol particles and apoli-
poprotein B. Fenofibrate is particularly successful for
reducing postprandial VLDL and LDL particle and oxi-
dative stress and inflammatory response after a fatty
meal [27]. Fibrate therapy results in significant reduc-
tions in fasting triglyceride concentrations and has been
shown to reduce fibrinogen and C-reactive protein in in-
flammatory mediators [28].
With the best of our knowledge, this is the first study on
the effectiveness of combination therapy with a fibrate
(Gemfibrozil) and ezetimibe on reducing fasting and post-
prandial TG levels. Most of the previous studies have fo-
cused on the effectiveness of combination therapy with
ezetimibe and statines. The others have investigated the
effect of fibrate monotherapy on postprandial TG concen-
tration or the effect of coadminestering ezetimibe and
fenofibrate on fasting and not postprandial TG [26,29]. We
found that the reduction rate of TG after treatment is cor-
related negatively to the baseline TG levels. Such result has
been previously reported by Farnier in a review article [29].
We acknowledge some limitations of our study. Due
to the short duration of the present study (6 weeks),
conclusions about long-term efficacy and safety cannot
be made. Additionally, patients were recruited with spe-
cific inclusion and exclusion criteria and thus extension
of these results to other populations should be done
with caution. However, long-term efficacy, durability and
tolerability have been demonstrated in studies up to 48
weeks with ezetimibe co-administered with either simva-
statin [30] or atorvastatin [31].
Conclusion
Although adding ezetimibe to gemfibrozil has no add-
itional effect on reducing postprandial TG but ezetimibe
can potentiate the effect of low-dose atorvastatin on
lowering TG and LDL-c. Based on the results of this
study, a fibrate agent (gemfibrozil) is one of the best to
control postprandial hypertriglyceridemia. For patients
with diabetes mellitus type 2 and pure hypertriglyc-
eridemia, monotherapy with gemfibrozil might be a good
choice especially in those with low HDL-c.
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